Women taking tamoxifen for breast cancer prevention don't need regular uterine biopsies to detect early endometrial cancer. Abnormal vaginal bleeding is a more effective indicator of the rare but curable condition.
Researchers found that 6-beta naltrexol, a metabolite of naltrexone, can reduce alcohol drinking in rats. The study suggests that 6-beta naltrexol is a potential new medication for treating alcohol dependence.
The current medical research protocols are out of step with evidence-based medicine and new technology developments, suggests an analysis in the Journal of Medical Ethics. Patients taking part in research deserve the same safety and regulation standards as public transport passengers, yet often receive inadequate care.
A study in Alcoholism: Clinical & Experimental Research examines gender-specific reasons for treatment retention in private substance abuse treatment programs. Women's staying power is linked to being unemployed, married, and having higher incomes, while men's staying power is related to receiving employer pressure and having a goal to...
Researchers at the National Institute on Drug Abuse found that squirrel monkeys will self-administer intravenous injections of THC, a psychoactive compound in marijuana, in doses comparable to those used by humans. This study suggests that marijuana has similar abuse potential as other addictive substances like cocaine and heroin.
A study in mice found that genetic background influences blood-pressure response to acute alcohol exposure, with some strains experiencing increased blood pressure and others not. The findings suggest a predisposition to greater increases in blood pressure with alcohol consumption, potentially leading to hypertension.
New research found that 13 of 50 people with primary pulmonary hypertension shared a genetic defect in the BMPR-II gene, similar to those with familial forms. This discovery has important implications for treatment and future therapies focused on altered cell signals.
Researchers used frog extracts to study DNA replication in Bloom's Syndrome, finding the protein essential for this process. This discovery may lead to new treatments for human cancer, as the protein is likely to have the same function in humans.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.